Jia Ruan, MD, PhD from the Weill Cornell Medical College in New York (USA), discusses a Phase II study aiming to evaluate the efficacy and safety of combined azacitidine and CHOP as initial treatment in peripheral T-cell lymphoma (PTCL) patients.